• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Merck

HHS gives Vaxxas $22M to support vaccine patch tech

October 5, 2020 By Chris Newmarker

Vaxxas micropatch vaccine COVID-19

Vaxxas announced today that it has received a $22 million award from the Biomedical Advanced Research and Development Authority (BARDA) at U.S. HHS to support a clinical study involving the company’s vaccine-delivery patch. The money will mostly pay for a Phase 1 clinical study in which Vaxxas’ high-density micro-array patch (HD-MAP) delivering pandemic influenza vaccine […]

Filed Under: Drug-Device Combinations, Featured, Funding Roundup Tagged With: BARDA, coronavirus, COVID-19, HHS, Merck, Vaxxas

Could Vaxxas’ tiny patches enable a better COVID-19 vaccine?

September 2, 2020 By Chris Newmarker

Vaxxas micropatch vaccine COVID-19

Tiny vaccine delivery patches could solve logistical challenges, but they face manufacturing hurdles. Here’s how Vaxxas is trying to overcome them. Merck (NYSE:MRK) and Vaxxas announced earlier this year that the pharmaceutical giant was using Vaxxas’ High Density Microarray Patch (HD-MAP) platform as a delivery platform for a vaccine candidate. Vaxxas did not disclose what […]

Filed Under: Drug-Device Combinations, Featured, Pharmaceuticals Tagged With: coronavirus, COVID-19, Harro Höfliger, Merck, Vaxxas

Merck eyes tiny patches as a vaccine delivery method

May 28, 2020 By Chris Newmarker

Vaxxas HD-MAP micropatch vaccines

Merck has exercised its option to use Vaxxas‘ High Density Microarray Patch (HD-MAP) platform as a delivery platform for a vaccine candidate, the companies announced today. The companies did not disclose what the vaccine candidate is supposed to treat. But Merck this month announced two COVID-19 vaccine development efforts: a collaboration with IAVI and plans […]

Filed Under: Business/Financial News, Drug-Device Combinations, Featured, Pharmaceuticals Tagged With: coronavirus, COVID-19, Harro Höfliger, Merck, Vaxxas

Prasco launches generic NuvaRing

December 17, 2019 By Danielle Kirsh

prasco

Prasco this week said it launched its authorized generic NuvaRing. The generic etonogestrel/ethinyl vaginal ring is a small, flexible vaginal ring that is used by women as a form of birth control. The NuvaRing releases a continuous low dose of hormones for three weeks at a time. “We are proud to launch the authorized generic […]

Filed Under: Women's Health Tagged With: Merck, Prasco

OncoSec shares fall on preliminary data from skin cancer trial

November 6, 2018 By Sarah Faulkner

OncoSec

Shares in OncoSec Medical (NSDQ:ONCS) fell nearly -60% this morning after the company revealed preliminary data from its Phase IIb trial of intratumoral delivery of Tavo in people with unresectable, advanced melanoma. OncoSec’s lead product, Tavo, uses electroporation to deliver IL-12 directly into a patient’s tumor, triggering an immune response. As of Sept. 1, 21 people […]

Filed Under: Clinical Trials, Drug-Device Combinations, Featured, Immunotherapy, Oncology, Pharmaceuticals, Wall Street Beat Tagged With: Bristol-Myers Squibb Co., Merck, OncoSec Medical

FDA warns of flesh-eating genital infection linked to diabetes drug

August 31, 2018 By Fink Densford

FDA

The FDA this week warned of serious flesh-eating bacterial infections, or necrotizing fasciitis, reported by patients taking sodium-glucose cotransporter-2 (SGLT2) inhibitors intended for treating type 2 diabetes. The federal watchdog said that between March 2013 and May 2018, 12 cases of Fournier’s gangrene, a rare but life-threatening bacterial infection of the tissue under the skin […]

Filed Under: Diabetes, Featured, Food & Drug Administration (FDA), Pharmaceuticals Tagged With: AstraZeneca plc, Bristol-Myers Squibb Co., Eli Lilly & Co., johnsonandjohnson, Merck, Pfizer Inc.

GlucoMe, Merck ink Vietnamese diabetes study deal

August 27, 2018 By Fink Densford

GlucoMe, Merck

GlucoMe said last week it inked a pilot collaboration deal with Merck (NYSE:MRK) looking to evaluate GlucoMe’s digital diabetes platform at several hospitals in Vietnam. Israel-based GlucoMe said that the project was scheduled to begin this month, and that it will compare GlucoMe’s digital diabetes care system against the current standard of care in the country. The […]

Filed Under: Business/Financial News, Clinical Trials, Diabetes, Featured Tagged With: GlucoMe, Merck

Study: Heat-stable drug formulation offers new option to prevent postpartum bleeding

June 28, 2018 By Sarah Faulkner

Ferring Pharmaceuticals

Data from a collaboration between Ferring Pharmaceuticals, Merck (NYSE:MRK) and the World Health Organization showed that a heat-stable formulation of carbetocin is as effective as oxytocin for the prevention of excessive bleeding following vaginal birth. Millions of women are affected by postpartum hemorrhage every year, according to Ferring Pharmaceuticals. Traditionally, women are given oxytocin to prevent […]

Filed Under: Clinical Trials, Featured, Pharmaceuticals, Wall Street Beat, Women's Health Tagged With: ferringpharmaceuticals, Merck, World Health Organization

OncoSec to combine ImmunoPulse device with Merck’s immunotherapy in breast cancer trial

May 8, 2018 By Sarah Faulkner

OncoSec

OncoSec Medical (NSDQ:ONCS) expanded its relationship with Merck (NYSE:MRK) today, announcing a deal to combine its ImmunoPulse IL-12 device with Merck’s anti-PD-1 therapy, Keytruda, in a Phase II trial of patients with triple negative breast cancer. The trial is slated to study the drug-device combination in patients with inoperable locally advanced or metastatic cancer who have failed […]

Filed Under: Clinical Trials, Drug-Device Combinations, Featured, Immunotherapy, Oncology, Pharmaceuticals, Wall Street Beat Tagged With: Merck, OncoSec Medical

Report: Pharma companies ask Supremes to take eye-dropper case

April 2, 2018 By Sarah Faulkner

gavel

A group of pharmaceutical companies, including Allergan (NYSE:AGN) and Merck (NYSE:MRK), have asked the Supreme Court to review a case between the industry players and patients regarding the design of the companies’ eye-droppers, according to a report from the AP. In the on-going legal debate, patient groups have claimed that the companies’ devices dispense large drops of medication […]

Filed Under: Drug-Device Combinations, Featured, Legal News, Optical/Ophthalmic, Pharmaceuticals, Wall Street Beat Tagged With: Allergan, Merck, Pfizer Inc.

  • Go to page 1
  • Go to page 2
  • Go to page 3
  • Interim pages omitted …
  • Go to page 6
  • Go to Next Page »

Primary Sidebar

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Need Drug Delivery Business News in a minute? We Deliver!
Drug Delivery Enewsletters get you caught up on all the mission critical news you need in med tech. Sign up today.

Tweets by DrugDeliveryNow

Footer

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Design & Outsourcing
Medical Tubing + Extrusion

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery News
Advertise with us
About
Contact us
Privacy
Add us on FacebookFollow us on TwitterConnect with us on LinkedIn

Copyright © 2021 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Advertise | Privacy Policy | RSS